13 Feb NEW OAB MEDICATION GEMTESA WILL BE AVAILABLE APRIL 2021
In December 2020, Urovant gained FDA approval of its NDA (New Drug Application) for once-daily 75mg GEMTESA® (vibegron), which is a beta-3 receptor agonist. The medication will be available April 2021. The onset of action is faster like current anti-cholinergics without the often-intolerable side effects...